Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

profileCarole Diane Mitnick, Sc.D.

TitleAssociate Professor of Global Health and Social Medicine
InstitutionHarvard Medical School
DepartmentGlobal Health and Social Medicine
AddressHarvard Medical School
Social Medicine
641 Huntington Ave
Boston MA 02115
Phone617/432-6018
Fax617/432-6045
vCardDownload vCard (login for email)

Collapse Mentoring 
Collapse completed student projects
Detection of hypertension as risk factor in chronic kidney disease and access to medical care in Quezalguaque, Leon, Nicaragua
International, 06/16/10 - 08/08/10
Spanish and Service Learning Program in Santiago, Chile 2005
International, 06/19/05 - 08/12/05
Chile Spanish Language and Service Learning Program 2005
International, 06/20/05 - 08/12/05
An assessment of the efficacy, access-to-care, and sustainability of a recently established national cataract elimination program in Peru
International, 06/18/09 - 08/10/09
Service Learning Program in Santiago, Chile - summer 2005
Spanish, 06/19/05 - 08/12/05

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
U01AI091429     (MITNICK, CAROLE D)Aug 20, 2011 - Jul 31, 2014
NIH/NIAID
Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB
Role: Co-Principal Investigator

R34AI073369     (MITNICK, CAROLE D)Jul 15, 2007 - Jun 30, 2010
NIH/NIAID
Randomized Trial of High-Dose Rifampin in Patients with New, Smear-Positive TB
Role: Principal Investigator

K01AI065836     (MITNICK, CAROLE D)Sep 15, 2006 - Aug 31, 2010
NIH/NIAID
Clinical Outcomes Research in MDR-TB
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB. Feasibility and yield of screening for non-communicable diseases among treated tuberculosis patients in Peru. Int J Tuberc Lung Dis. 2018 Jan 01; 22(1):86-92. PMID: 29297431.
    View in: PubMed
  2. Varaine F, Guglielmetti L, Mitnick CD. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. Am J Respir Crit Care Med. 2017 12 01; 196(11):1490-1491. PMID: 28715258.
    View in: PubMed
  3. Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017 Nov 25; 18(1):563. PMID: 29178937.
    View in: PubMed
  4. Farhat MR, Jacobson KR, Franke MF, Kaur D, Murray M, Mitnick CD. Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. Clin Infect Dis. 2017 Oct 15; 65(8):1364-1370. PMID: 29017248.
    View in: PubMed
  5. Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Garavito ES, Vasquez DV, Mitnick CD, Davies G. Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis". Antimicrob Agents Chemother. 2017 Sep; 61(9). PMID: 28839086.
    View in: PubMed
  6. Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017 Aug 01; 21(8):894-901. PMID: 28786798.
    View in: PubMed
  7. Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 Aug; 61(8). PMID: 28559269.
    View in: PubMed
  8. Byrne AL, Marais BJ, Mitnick CD, Garden FL, Lecca L, Contreras C, Yauri Y, Garcia F, Marks GB. Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis. ERJ Open Res. 2017 Jul; 3(3). PMID: 28717643.
    View in: PubMed
  9. Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB. Erratum for Velásquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017 Mar; 61(3). PMID: 28232308.
    View in: PubMed
  10. Nourzad S, Jenkins HE, Milstein M, Mitnick CD. Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis. Int J Tuberc Lung Dis. 2017 Jan 01; 21(1):6-11. PMID: 28157458.
    View in: PubMed
  11. Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. Int J Infect Dis. 2017 Mar; 56:185-189. PMID: 28007660.
    View in: PubMed
  12. Horsburgh CR, Rusen ID, Mitnick CD. Optimizing MDR-TB clinical trials: insights from the first global MDR-TB Clinical Trials Landscape Meeting. Int J Tuberc Lung Dis. 2016 Dec 01; 20(12):1-3. PMID: 28240564.
    View in: PubMed
  13. Milstein M, Brzezinski A, Varaine F, Mitnick CD. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 Dec 01; 20(12):18-23. PMID: 28240568.
    View in: PubMed
  14. Cellamare M, Milstein M, Ventz S, Baudin E, Trippa L, Mitnick CD. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis. 2016 Dec 01; 20(12):8-12. PMID: 28240566.
    View in: PubMed
  15. Guglielmetti L, Le Dû D, Fréchet-Jachym M, Mitnick C. Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management. Am J Respir Crit Care Med. 2016 11 01; 194(9):1170-1171. PMID: 27797614.
    View in: PubMed
  16. Tierney DB, Milstein MB, Manjourides J, Furin JJ, Mitnick CD. Treatment Outcomes for Adolescents With Multidrug-Resistant Tuberculosis in Lima, Peru. Glob Pediatr Health. 2016; 3:2333794X16674382. PMID: 27826599.
    View in: PubMed
  17. Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2016 Nov; 60(11):6766-6773. PMID: 27600032.
    View in: PubMed
  18. Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD. Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations. Am J Respir Crit Care Med. 2016 10 15; 194(8):1028-1029. PMID: 27739887.
    View in: PubMed
  19. Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L. A Bayesian response-adaptive trial in tuberculosis: The endTB trial. Clin Trials. 2017 Feb; 14(1):17-28. PMID: 27559021.
    View in: PubMed
  20. Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016 Oct; 48(4):1160-1170. PMID: 27587552.
    View in: PubMed
  21. Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 08 27; 16(1):453. PMID: 27567500; PMCID: PMC5002098.
  22. Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F. Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One. 2016; 11(5):e0155968. PMID: 27223622; PMCID: PMC4880345.
  23. Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS One. 2016; 11(3):e0151724. PMID: 27022741; PMCID: PMC4811416.
  24. Parr JB, Rich ML, Keshavjee S, Franke MF, Mitnick CD, Bayona J, Becerra MC. Presumptive treatment of multidrug-resistant tuberculosis in household contacts. Int J Tuberc Lung Dis. 2016 Mar; 20(3):370-5. PMID: 27046719.
    View in: PubMed
  25. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-4. PMID: 27046707; PMCID: PMC4843774.
  26. Mitnick C, van den Hof S. Using existing data to illustrate--and close--the gap in access to new anti-tuberculosis drugs. Int J Tuberc Lung Dis. 2016 Feb; 20(2):145. PMID: 26792461.
    View in: PubMed
  27. Odone A, Calderon R, Becerra MC, Zhang Z, Contreras CC, Yataco R, Galea J, Lecca L, Bonds MH, Mitnick CD, Murray MB. Acquired and Transmitted Multidrug Resistant Tuberculosis: The Role of Social Determinants. PLoS One. 2016; 11(1):e0146642. PMID: 26765328; PMCID: PMC4713093.
  28. Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2016 Mar; 54(3):727-33. PMID: 26763957; PMCID: PMC4767988.
  29. Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis. 2016 Apr 01; 62(7):887-895. PMID: 26757804.
    View in: PubMed
  30. Cox HS, Furin JJ, Mitnick CD, Daniels C, Cox V, Goemaere E. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bull World Health Organ. 2015 Jul 01; 93(7):491-7. PMID: 26170507; PMCID: PMC4490806.
  31. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Risk factors for and origins of COPD. Lancet. 2015 May 02; 385(9979):1723-1724. PMID: 25943930.
    View in: PubMed
  32. Franke MF, Becerra MC, Tierney DB, Rich ML, Bonilla C, Bayona J, McLaughlin MM, Mitnick CD. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc. 2015 May; 12(5):674-9. PMID: 25664920; PMCID: PMC4418338.
  33. Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J. QTc prolongation and treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015 Apr; 19(4):385-91. PMID: 25859992.
    View in: PubMed
  34. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015 Mar; 32:138-46. PMID: 25809770.
    View in: PubMed
  35. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis. 2015 Mar; 19(3):339-41. PMID: 25686144; PMCID: PMC4486051.
  36. Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. Int J Infect Dis. 2015 Mar; 32:56-60. PMID: 25809757.
    View in: PubMed
  37. Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova OV, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazennyy B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, Viiklepp P, Volchenkov G, Walker AT, Wolfgang M, Yagui M, Zignol M. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015 Mar; 3(3):201-9. PMID: 25726085; PMCID: PMC4401426.
  38. Tierney DB, Franke MF, Becerra MC, Alcántara Virú FA, Bonilla CA, Sánchez E, Guerra D, Muñoz M, Llaro K, Palacios E, Mestanza L, Hurtado RM, Furin JJ, Shin S, Mitnick CD. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoS One. 2014; 9(9):e108035. PMID: 25238411; PMCID: PMC4169600.
  39. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014 Jul 01; 59(1):9-15. PMID: 24729493; PMCID: PMC4305127.
  40. Parr JB, Mitnick CD, Atwood SS, Chalco K, Bayona J, Becerra MC. Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2014 Feb; 58(3):392-5. PMID: 24170196; PMCID: PMC3890336.
  41. Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014 Jan 01; 92(1):68-74. PMID: 24391302; PMCID: PMC3865549.
  42. Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill. 2013 Oct 03; 18(40). PMID: 24128699.
    View in: PubMed
  43. Seung KJ, Becerra MC, Atwood SS, Alcántara F, Bonilla CA, Mitnick CD. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect. 2014 May; 20(5):441-6. PMID: 23991934.
    View in: PubMed
  44. Palazuelos D, Ellis K, Im DD, Peckarsky M, Schwarz D, Farmer DB, Dhillon R, Johnson A, Orihuela C, Hackett J, Bazile J, Berman L, Ballard M, Panjabi R, Ternier R, Slavin S, Lee S, Selinsky S, Mitnick CD. 5-SPICE: the application of an original framework for community health worker program design, quality improvement and research agenda setting. Glob Health Action. 2013 Apr 03; 6:19658. PMID: 23561023; PMCID: PMC3617878.
  45. Mitnick CD, Keravec J, Cohen T. Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB. Int J Tuberc Lung Dis. 2013 Apr; 17(4):427-8. PMID: 23485374.
    View in: PubMed
  46. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HS, Furin JJ, Guerra D, Hurtado RM, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Seung KJ, Shin SS, Sloutsky A, Tolman AW, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664. PMID: 23516529; PMCID: PMC3596279.
  47. Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One. 2013; 8(2):e56074. PMID: 23457502; PMCID: PMC3574085.
  48. Becerra MC, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, Mitnick CD. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatr Infect Dis J. 2013 Feb; 32(2):115-9. PMID: 22926210.
    View in: PubMed
  49. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, Shin S, Murray M, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013 Mar; 56(6):770-6. PMID: 23223591; PMCID: PMC3582355.
  50. Kurbatova EV, Gammino VM, Bayona J, Becerra MC, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1335-43. PMID: 23107633.
    View in: PubMed
  51. Dooley KE, Mitnick C, Degroote MA, Obuku E, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E. Reply to Seddon, Schaaf, and Hesseling. Clin Infect Dis. 2013 Jan; 56(1):168-9. PMID: 22990846; PMCID: PMC4447816.
  52. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez-Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300. PMID: 22952439; PMCID: PMC3429397.
  53. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013 May 01; 207(9):1352-8. PMID: 22807518; PMCID: PMC3693592.
  54. Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Viiklepp P, Zignol M, Cegielski JP. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012 Sep; 92(5):397-403. PMID: 22789497; PMCID: PMC4749016.
  55. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J. 2012 Jul; 40(1):9-11. PMID: 22753833.
    View in: PubMed
  56. Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012 Jul; 15(3 Suppl):ES59-66. PMID: 22786462.
    View in: PubMed
  57. Dooley KE, Mitnick CD, Ann DeGroote M, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis. 2012 Aug; 55(4):572-81. PMID: 22615332; PMCID: PMC3520382.
  58. Alexy ER, Podewils LJ, Mitnick CD, Becerra MC, Laserson KF, Bonilla C. Concordance of programmatic and laboratory-based multidrug-resistant tuberculosis treatment outcomes in Peru. Int J Tuberc Lung Dis. 2012; 16(3):364-9. PMID: 22640451; PMCID: PMC4616001.
  59. Furin J, Gegia M, Mitnick C, Rich M, Shin S, Becerra M, Drobac P, Farmer P, Hurtado R, Joseph JK, Keshavjee S, Kalandadze I. Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bull World Health Organ. 2012 Jan 01; 90(1):63-6. PMID: 22271966; PMCID: PMC3260578.
  60. Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment. Int J Tuberc Lung Dis. 2011 Nov; 15(11):1553-5, i. PMID: 22008772.
    View in: PubMed
  61. Gammino VM, Taylor AB, Rich ML, Bayona J, Becerra MC, Bonilla C, Gelmanova I, Hollo V, Jaramillo E, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riektsina V, Tupasi TE, Wells CD, Zignol M, Cegielski PJ. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis. 2011 Oct; 15(10):1315-22. PMID: 22283887.
    View in: PubMed
  62. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011 Sep; 38(3):516-28. PMID: 21828024.
    View in: PubMed
  63. Izu A, Cohen T, Mitnick C, Murray M, De Gruttola V. Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains. Stat Med. 2011 Sep 30; 30(22):2708-20. PMID: 21717491; PMCID: PMC3219798.
  64. Cox H, Ford N, Keshavjee S, McDermid C, von Schoen-Angerer T, Mitnick C, Goemaere E. Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis. 2011 Apr; 11(4):259-60. PMID: 21453864.
    View in: PubMed
  65. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, Murray M, Atwood SS, Mitnick CD. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011 Jan 08; 377(9760):147-52. PMID: 21145581.
    View in: PubMed
  66. Mitnick C, Horsburgh CR. Encouraging news for multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010 Dec 01; 182(11):1337-8. PMID: 21123746.
    View in: PubMed
  67. Stryjewski TP, Benadretti DB, Zhao SD, Rowe S, Mitnick CD. Preliminary clinical outcomes from the Peruvian National Cataract Elimination Plan. Rev Panam Salud Publica. 2010 Oct; 28(4):282-8. PMID: 21152716.
    View in: PubMed
  68. Becerra MC, Appleton SC, Franke MF, Chalco K, Bayona J, Murray MB, Mitnick CD. Recurrence after treatment for pulmonary multidrug-resistant tuberculosis. Clin Infect Dis. 2010 Sep 15; 51(6):709-11. PMID: 20687835.
    View in: PubMed
  69. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010 Jul 01; 51(1):6-14. PMID: 20504231; PMCID: PMC4013786.
  70. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother. 2009 Feb; 10(3):381-401. PMID: 19191677; PMCID: PMC2674232.
  71. Mitnick CD, Appleton SC, Shin SS. Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med. 2008 Oct; 29(5):499-524. PMID: 18810684; PMCID: PMC2834421.
  72. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C, Asencios L, Mendoza A, Bayona J, Zignol M, Jaramillo E. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One. 2008 Aug 13; 3(8):e2957. PMID: 18698423; PMCID: PMC2495032.
  73. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74. PMID: 18687637; PMCID: PMC2673722.
  74. Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, Rieder HL, Weyer K, Zignol M. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med. 2008 Jul 08; 5(7):e150. PMID: 18613746; PMCID: PMC2443187.
  75. Franke MF, Appleton SC, Bayona J, Arteaga F, Palacios E, Llaro K, Shin SS, Becerra MC, Murray MB, Mitnick CD. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis. 2008 Jun 15; 46(12):1844-51. PMID: 18462099; PMCID: PMC2577177.
  76. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007 Nov 06; 4(11):e292. PMID: 17988168; PMCID: PMC2062482.
  77. Nardell EA, Mitnick CD. Are second-line drugs necessary to control multidrug-resistant tuberculosis? J Infect Dis. 2006 Nov 01; 194(9):1194-6. PMID: 17041843.
    View in: PubMed
  78. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P, Pasechnikov A, Tupasi T, Wells C, Raviglione MC. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis. 2006 Sep; 12(9):1389-97. PMID: 17073088; PMCID: PMC3294733.
  79. Drobac PC, Mukherjee JS, Joseph JK, Mitnick C, Furin JJ, del Castillo H, Shin SS, Becerra MC. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006 Jun; 117(6):2022-9. PMID: 16740844.
    View in: PubMed
  80. Shin SS, Furin JJ, Alcántara F, Bayona J, Sánchez E, Mitnick CD. Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis. 2006 Apr; 12(4):687-8. PMID: 16704823; PMCID: PMC3294679.
  81. Rich ML, Socci AR, Mitnick CD, Nardell EA, Becerra MC, Bonilla C, Bayona J, Seung KJ, Furin J, Farmer PE, Mukherjee JS. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006 Mar; 10(3):290-6. PMID: 16562709.
    View in: PubMed
  82. Heldal E, Gammino V, Hollo V, Laserson K, Mitnick C, Rich M, Trebucq A. Category IV recording and reporting system. Stop TB Department, World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuerculosis. 2006; 114-123.
  83. Heldal E, Gammino V, Hollo V, Laserson K, Mitnick C, Rich M, Trebucq A. Definitions: case registration, bacteriology and treatment outcomes. Stop TB Department, World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2006; 18-23.
  84. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcón E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Jun; 9(6):640-5. PMID: 15971391.
    View in: PubMed
  85. Mitnick, CD. Operational Research in Tuberculosis. 2005.
  86. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004 Mar; 8(3):361-8. PMID: 15139476.
    View in: PubMed
  87. Choi SS, Jazayeri DG, Mitnick CD, Chalco K, Bayona J, Fraser HS. Implementation and initial evaluation of a Web-based nurse order entry system for multidrug-resistant tuberculosis patients in Peru. Stud Health Technol Inform. 2004; 107(Pt 1):202-6. PMID: 15360803.
    View in: PubMed
  88. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick CD. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis. 2004 Jan; 8(1):52-8. PMID: 14974746.
    View in: PubMed
  89. Shin SS, Hyson AM, Castañeda C, Sánchez E, Alcántara F, Mitnick CD, Fawzi MC, Bayona J, Farmer PE, Kim JY, Furin JJ. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2003 Apr; 7(4):347-53. PMID: 12729340.
    View in: PubMed
  90. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Fawzi MC, Kapiga S, Neuberg D, Maguire JH, Kim JY, Farmer P. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003 Jan 09; 348(2):119-28. PMID: 12519922.
    View in: PubMed
  91. Partners In Health. The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis. 2003.
  92. Partners In Health/Program in Infectious Disease and Social Change. A Dots-Plus Handbook: Guide to the Community-Based Treatment of MDR-TB. 2002.
  93. Fraser HS, Jazayeri D, Mitnick CD, Mukherjee JS, Bayona J. Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proc AMIA Symp. 2002; 270-4. PMID: 12463829; PMCID: PMC2244209.
  94. Kim JY, Mitnick CD, Bayona J, Blank R, Nardell E, Mukherjee JS, Rich ML, Farmer PE, Becerra MC, Murray M. Examing assumptions about multidrug-resistant TB control. Bulletin of the World Health Organization. 2002; 80(6):498-9.
  95. Program in Infectious Disease and Social Change in consultation with Stop TB Department, World Health Organization. Statement on the Role of the Corporate Sector in Global Tuberculosis Control. 2002.
  96. Fraser HS, Jazayeri D, Mitnick CD, Mukherjee JS, Bayona J. Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proceedings of AMIA Symposium. 2002; 270-4.
  97. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, Alcantara F, Castañieda C, Sanchez E, Acha J, Farmer PE, Kim JY. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001 Jul; 5(7):648-55. PMID: 11467371.
    View in: PubMed
  98. Mitnick, CD. Outcomes of Directly Observed, Individualized Community-Based Therapy for Multidrug-Resistant Tuberculosis in a Shantytown in Northern Lima, Peru. 2001.
  99. Widmer S, Mitnick C, editors. Review of Tuberculosis Control Programs in Eastern and Central Europe and the Former Soviet Union. 2001.
  100. Mitnick, CD. Poverty, Culture and Infectious Diseases. 2000.
  101. Farmer PE, Kim JY, Mitnick CD, Timperi R. Responding to outbreaks of MDR-TB: introducing DOTS-plus. Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. 2000; 447-69.
  102. Mitnick, CD. Health of Prisoners. 1999.
  103. Farmer P, Furin J, Bayona J, Becerra M, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S. Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis. 1999 Aug; 3(8):643-5. PMID: 10460095.
    View in: PubMed
  104. Mitnick CD, Farmer PE. . Promise and peril: TB and multidrug-resistant tuberculosis in Azerbaijan. Farmer PE, Becerra M, Kim JY, eds. The Global Impact of Drug-Resistant Tuberculosis. 1999; 87-105..
  105. Farmer PE, Bayona J, Becerra M, Furin J, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S. DOTS plus strategy in resource-poor countries. International Journal of Tuberculosis and Lung Disease. 1999; 3(9):844.
  106. Farmer P, Bayona J, Becerra M, Furin J, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998 Nov; 2(11):869-76. PMID: 9848606.
    View in: PubMed
  107. Mitnick C, Furin J, Henry C, Ross J. Tuberculosis among the foreign born in Massachusetts, 1982-1994: a reflection of social and economic disadvantage. Int J Tuberc Lung Dis. 1998 Sep; 2(9 Suppl 1):S32-40. PMID: 9755963.
    View in: PubMed
  108. Mitnick C, Furin J, Henry C, Ross J. Tuberculosis among the foreign born in Massachusetts, 1982-1994: a reflection of social and economic disadvantage [The Eddie O'Brien Lecture]. Int J Tuberc Lung Dis. 1998 Sep 01; 2(9):32-40. PMID: 29343325.
    View in: PubMed
  109. Partners In Health. Normes et procedures du traitement de la tuberculose. Clinique Bon Sauveur, Zanmi Lasante. 1998.
  110. Fawzi MC, Jean-Baptiste M, Rosenthal B, Mitnick C. Health impact of human rights violations in Haitian refugees. Lancet. 1997 Aug 02; 350(9074):371-2. PMID: 9251672.
    View in: PubMed
  111. Farmer P, Bayona J, Becerra M, Daily J, Furin J, Garcia D, Henry C, Kim J, Mitnick C, Nardell E, Raymonville M, Shin S, Small P. Poverty, inequality and drug resistance: meeting community needs. Proceedings of the International Union Against Tuberculosis and Lung Disease. 1997; 88-102.
  112. Mitnick, CD. Consumption of the Poor: Tuberculosis in the 20th Century. 1996.
  113. Holmes A, Barnett E, Mitnick C, Phillips S, Gas M, Wais M, Wilson M. . The development of an appropriate screening and treatment strategy for schistosomiasis in the Somalian refugee population followed at Boston City Hospital's International Clinic. Proceedings of the Infectious Disease Society of America, 33rd Meeting. 1995.
  114. Mitnick, CD. Evaluation and Monitoring of Public Health Interventions in Developing Countries. 1995.
  115. Mitnick, C. Epidemiology of Infectious Diseases of Importance in Developing Countries. 1994.
  116. Wilson A, Michaels B, Mitnick C, editors. Malaria and Development in Sub-Saharan Africa. 1991.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mitnick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_